Enalapril in African patients with congestive cardiac failure.

Ajayi, A. A.; Balogun, M. O.; Oyewo, E. A.; Ladipo, G. O. A.

doi:10.1111/j.1365-2125.1989.tb05385.x

Cited by 8 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been smaller trials that confirmed the effectiveness of ACEis and b-blockers in patients from Africa and Asia. 504,509 Because of the fundamental nature of the derangements in HF, it is likely that the current treatment approach such as blockade of neurohormonal activation and the judicious use of devices will be similarly effective, although one cannot rule out the possibility that the degree of response to treatment might vary among ethnic groups. Details that pertain to specific minority populations are available in section 7.5.2.2 of the Supplementary Material.…”

Section: General Considerationsmentioning

confidence: 99%

2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure

Ezekowitz

O’Meara

McDonald

et al. 2017

Canadian Journal of Cardiology

554

496

View full text Add to dashboard Cite

Since the inception of the Canadian Cardiovascular Society heart failure (HF) guidelines in 2006, much has changed in the care for patients with HF. Over the past decade, the HF Guidelines Committee has published regular updates. However, because of the major changes that have occurred, the Guidelines Committee believes that a comprehensive reassessment of the HF management recommendations is presently needed, with a view to producing a full and complete set of updated guidelines. The primary and secondary Canadian Cardiovascular Society HF panel members as well as external experts have reviewed clinically relevant literature to provide guidance for the practicing clinician. The 2017 HF guidelines provide updated guidance on the diagnosis and management (self-care, pharmacologic, nonpharmacologic, device, and referral) that should aid in day-to-day decisions for caring for patients with HF. Among specific issues covered are risk scores, the differences in management for HF with preserved vs reduced ejection fraction, exercise and rehabilitation, implantable devices, revascularization, right ventricular dysfunction, anemia, and iron deficiency, cardiorenal syndrome, sleep apnea, cardiomyopathies, HF in pregnancy, cardio-oncology, and myocarditis. We devoted attention to strategies and treatments to prevent HF, to the organization of HF care, comorbidity management, as well as practical issues around the timing of referral and follow-up care. Recognition and treatment of advanced HF is another important aspect of this update, including how to select advanced therapies as well as end of life considerations. Finally, we acknowledge the remaining gaps in evidence that need to be filled by future research.

show abstract

Section: General Considerationsmentioning

confidence: 99%

2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure

Ezekowitz

O’Meara

McDonald

et al. 2017

Canadian Journal of Cardiology

554

496

View full text Add to dashboard Cite

show abstract

“…With respect to the treatment of patients with HF, relatively few large-scale randomized controlled intervention trials in HF have included regions outside Europe and the US. Smaller clinical trials (6,7) have shown the effectiveness of ACE inhibitors and betablockers in HF patients from Africa and Asia. Given the fundamental nature of the derangements in HF, our current approach, including neurohormonal blockade and the appropriate use of devices, will likely be effective, although dosages and responses may differ slightly among ethnic groups.…”

Section: General Considerationsmentioning

confidence: 99%